Company intelligence / Profile preview
Yantai Patronus Biotech Co., Ltd.
Yantai, Shandong Province, Chinaluye.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple vaccine candidates in clinical trials, with their COVID-19 vaccine LYB001 in Phase 2/3 trials with 18,000 participants enrolled[2][8]. They also have several other vaccines in Phase 1 trials, including a SARS-CoV-2 trivalent vaccine, a Recombinant Zoster Vaccine, and a Respiratory Syncytial Virus Vaccine[5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccinesProtein Subunit VaccinesVirus-Like Particles (VLP)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Yantai Patronus Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yantai Patronus Biotech Co., Ltd..